Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.32 |
| ▸ | YAP1 | P46937 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2853420 | 0.83 | ALDH1A1 (0.37) | MTNR1AMTNR1B | |
| SCHEMBL2863638 | 0.78 | HDAC1 (0.30) | — | |
| SCHEMBL2858711 | 0.78 | ALDH1A1 (0.31) | — | |
| SCHEMBL2861249 | 0.77 | PLA2G2A (0.44) | MTNR1AMTNR1B | |
| SCHEMBL2858297 | 0.72 | MTNR1A (0.41) | MTNR1AMTNR1B | |
| SCHEMBL4389660 | 0.68 | MTNR1A (0.42) | MTNR1AMTNR1B | |
| SCHEMBL4385656 | 0.67 | CA2 (0.35) | — | |
| SCHEMBL23605356 | 0.64 | KLK5 (0.47) | KLK5 | |
| SCHEMBL30250286 | 0.64 | KLK5 (0.47) | KLK5 | |
| SCHEMBL28956935 | 0.64 | KLK5 (0.47) | KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1911744-B1 | TRYPTOPHAN DERIVATIVE AND USE THEREOF | SOMEI MASANORI (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-7659304-B2 | Tryptophan derivative and application thereof | SOMEI MASANORI | 2010-02-09 | — | — | US | disclosed |
| US-7659304-B2 | Tryptophan derivative and application thereof | SOMEI MASANORI | 2010-02-09 | — | — | US | disclosed |
| US-7659304-B2 | Tryptophan derivative and application thereof | SOMEI MASANORI | 2010-02-09 | — | — | US | disclosed |
| US-20090054511-A1 | Tryptophan derivative and application thereof | SOMEI MASANORI | 2009-02-26 | — | — | US | disclosed |
| US-20090054511-A1 | Tryptophan derivative and application thereof | SOMEI MASANORI | 2009-02-26 | — | — | US | disclosed |
| US-20090054511-A1 | Tryptophan derivative and application thereof | SOMEI MASANORI | 2009-02-26 | — | — | US | disclosed |
| EP-1911744-A1 | TRYPTOPHAN DERIVATIVE AND USE THEREOF | Somei, Masanori (JP) | 2008-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054511-A1 | Tryptophan derivative and application thereof | TPH1, TPH2, AHR | MTNR1A 42/4885MTNR1B 93/4885KLK5 2805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.